Related Experiment Videos
Regulation of matrix biosynthesis and degradation in systemic sclerosis
1Boston University School of Medicine, Arthritis Center, Massachusetts 02118, USA. rwidom@medicine.bu.edu
Abstract:
The regulation of matrix biosynthesis in systemic sclerosis has been the focus of many studies, because excessive matrix synthesis causes pathologic changes, and because this would seem to be a good target for therapies aimed at ameliorating the disease. Possible targets for antifibrotic therapies include both matrix gene stimulatory and inhibitory pathways. Much recent progress has been made in understanding the mechanism of action of transforming growth factor-beta (TGF-beta), an important profibrotic cytokine with pleiotropic effects on fibroblasts. It appears that TGF-beta may use multiple signal transduction pathways in fibroblasts and it is possible that defects in any of these pathways may result in an abnormal response to TGF-beta, resulting in fibrosis. Studies on negative regulation of matrix gene expression have singled out the antifibrotic cytokines tumor necrosis factor-alpha and interferon-gamma. Finally, a new approach that compares mRNA expression in normal versus diseased fibroblasts has already lead to the discovery of genes that may play a role in the development of fibrosis. This represents an important advance because genes can be identified that have not previously been implicated in the control of matrix synthesis, and thus might not otherwise have been studied in this context.
Insights
Systemic sclerosis involves excessive matrix production. Therapies targeting matrix gene regulation, including transforming growth factor-beta (TGF-beta) pathways and novel gene discoveries, offer potential antifibrotic treatments.
Area of Science:
- Fibrosis research
- Connective tissue disorders
- Molecular biology
Background:
- Systemic sclerosis is characterized by excessive matrix biosynthesis, leading to pathological changes.
- Understanding matrix regulation is crucial for developing effective antifibrotic therapies.
Purpose of the Study:
- To explore targets for antifibrotic therapies in systemic sclerosis.
- To investigate the role of transforming growth factor-beta (TGF-beta) and other cytokines in matrix gene regulation.
Main Methods:
- Analysis of transforming growth factor-beta (TGF-beta) signaling pathways in fibroblasts.
- Examination of negative regulatory pathways involving tumor necrosis factor-alpha and interferon-gamma.
- Comparison of mRNA expression in normal versus diseased fibroblasts to identify novel genes.
Main Results:
- Transforming growth factor-beta (TGF-beta) is a key profibrotic cytokine potentially acting through multiple fibroblast signaling pathways.
- Tumor necrosis factor-alpha and interferon-gamma are identified as negative regulators of matrix gene expression.
- Novel genes implicated in fibrosis development have been discovered through comparative mRNA expression analysis.
Conclusions:
- Dysregulation in TGF-beta signaling pathways may contribute to fibrosis in systemic sclerosis.
- Identifying novel genes offers new avenues for understanding and treating fibrotic diseases.
- Targeting both stimulatory and inhibitory pathways provides a comprehensive strategy for antifibrotic therapy.